Alcresta Pharmaceuticals Inc.
Alcresta Pharmaceuticals Inc.
Enyzme products for gastrointestinal and rare diseases
Alcresta Pharmaceuticals Inc. aims to combat malabsorption, with an initial focus on enzyme deficiencies, for people with gastrointestinal disorders and rare diseases. It is developing a pipeline of point-of-care nutritional products tailored to maximize the absorption of calories or specific nutrients, based on cartridges enclosing enzymes immobilized onto polymer beads.
More from Archive
More from Scrip
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.